Drug Overview

Sheddase inhibitor INCB007839 is an experimental medicine designed to treat advanced cancers by blocking specific proteins on the surface of cancer cells. It is part of a modern group of treatments known as Targeted Therapy or “Smart Drugs.” This medication is highly specific, meaning it aims to interfere with the growth and spread of tumors while attempting to minimize damage to healthy parts of the body.

Because this is a specialized biological agent, it is currently available only to patients participating in approved medical research studies. It is not available for purchase at a standard pharmacy.

• Generic name: Sheddase inhibitor INCB007839 (also known as Aderbasib)
• US Brand names: None (Investigational drug)
• Drug Class: ADAM10 and ADAM17 inhibitor (Metalloprotease inhibitor)
• Route of Administration: Oral (taken by mouth as a pill)
• FDA Approval Status: Investigational (Not currently approved by the FDA for standard medical use)

What Is It and How Does It Work? (Mechanism of Action)

Sheddase inhibitor INCB007839 is a precision medicine that targets a family of enzymes called ADAM (A Disintegrin and Metalloproteinase), specifically ADAM10 and ADAM17. These enzymes are often called “sheddases” because they act like molecular scissors.

At the molecular level, cancer cells often have receiver antennas on their surface, such as the HER2 (Human Epidermal Growth Factor Receptor 2) receptor. Normally, these sheddase enzymes cut off parts of these receptors from the cell surface. This cutting process, or “shedding,” releases active signaling pieces into the body. These pieces then travel to other cells and send a powerful “growth” message, telling the cancer to multiply, survive, and spread to other organs.

INCB007839 works by binding directly to the ADAM10 and ADAM17 enzymes and “locking” their scissors. By stopping these enzymes from cutting the receptors, the drug prevents the release of these growth-driving pieces. This shuts down the communication pathways (such as the PI3K/AKT and MAPK pathways) that the tumor needs to survive. This targeted approach is especially useful when combined with other drugs like trastuzumab, as it helps keep the HER2 receptor intact on the cell surface so other therapies can find and destroy the cancer more effectively.

FDA Approved Clinical Indications

Because sheddase inhibitor INCB007839 is an investigational drug, it does not currently have official FDA-approved indications for general use. It has been evaluated in clinical trials for the following:

Oncological uses

• Investigational treatment for HER2-positive metastatic breast cancer (often in combination with trastuzumab).
• Investigational treatment for advanced solid tumors that have stopped responding to standard therapies.
• Investigational research into certain types of lymphoma.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, INCB007839 is administered as an oral tablet. The dosage is strictly determined by the research protocol for the specific type of cancer being treated.

Dose Adjustments

Because this drug is processed by the liver, careful monitoring is required. If blood tests show that liver enzymes are rising too high, doctors in clinical trials will pause the treatment or reduce the dose. There are no established dose starting rules for patients with renal (kidney) insufficiency, but kidney function is monitored throughout the study.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2025 has focused on how INCB007839 can overcome drug resistance in breast cancer.

Numerical data from Phase 2 studies showed that adding this sheddase inhibitor to standard trastuzumab therapy was helpful for a specific group of patients. In patients with HER2-positive metastatic breast cancer who had high levels of “shedded” receptor pieces in their blood, the combination treatment led to an objective response rate (tumor shrinkage) of approximately 40 percent. Furthermore, the median time before the disease got worse (progression-free survival) was approximately 7 months for those who responded well. While these results show the drug is active, researchers are still working to determine which patients will benefit the most before moving to larger trials.

Safety Profile and Side Effects

Like all targeted therapies, INCB007839 has a specific safety profile. Patients are monitored closely by their research team to manage any reactions.

Black Box Warning

There is no official FDA Black Box Warning for INCB007839 because it is not yet an approved medication.

Common side effects

These occur in more than 10 percent of patients:

• Diarrhea
• Nausea and vomiting
• Feeling very tired (fatigue)
• Skin rash
• Decreased appetite

Serious adverse events

• Significant increases in liver enzymes (indicating liver stress or inflammation).
• Potential for lung inflammation (interstitial lung disease).
• Severe dehydration resulting from diarrhea.

Management strategies

To manage diarrhea, doctors usually provide anti-diarrheal medications to be taken at the first sign of symptoms. If a patient feels nauseous, standard anti-nausea drugs are used. Because liver health is a priority, patients must have blood tests every 1 to 2 weeks. If liver markers become concerning, the medicine is stopped immediately until the liver recovers.

Research Areas

Sheddase inhibitor INCB007839 is a major topic of interest in “combination immunotherapy” research. Sheddase enzymes like ADAM17 are known to cut off important immune system markers that help the body’s natural T-cells find and kill cancer. Researchers are currently studying whether blocking these “scissors” with INCB007839 can prevent the cancer from hiding, thereby making modern immunotherapies much more effective. There is also early research into whether this drug can target “cancer stem cells,” which are the stubborn cells responsible for cancer coming back after treatment.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• A blood test to measure baseline liver function (ALT, AST, and Bilirubin).
• A complete blood count (CBC) to check white and red blood cell levels.
• Testing for HER2-positive status and, in some cases, measuring the amount of shedded receptor in the blood.
• A baseline physical exam and heart function check.

Precautions during treatment

Patients should be aware that skin rashes and diarrhea can happen quickly. It is vital to report these to the medical team immediately so they do not become severe.

Do’s and Don’ts list

• Do take the medication at the same time every day to keep levels steady in your blood.
• Do stay well-hydrated by drinking 8 glasses of water a day to help prevent kidney stress.
• Do report any yellowing of the skin or eyes (jaundice) right away.
• Don’t take any new herbal supplements or over-the-counter vitamins without asking your oncology team first.
• Don’t stop taking the medication suddenly unless directed by your research doctor.
• Don’t ignore a new cough or shortness of breath, as this could be a sign of lung irritation.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Sheddase inhibitor INCB007839 is an investigational medication and is not approved by the Food and Drug Administration to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment, managing side effects, or participating in a clinical research study.